Theseus Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Theseus Pharmaceuticals şirketinin toplam hissedar öz sermayesi $224.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $234.6M ve $10.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$205.12m
Eşitlik	US$224.52m
Toplam yükümlülükler	US$10.11m
Toplam varlıklar	US$234.63m

Son finansal sağlık güncellemeleri

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

Aug 18

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

May 05

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Dec 07

Recent updates

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Feb 01

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

Aug 18

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

May 05

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Dec 07

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Aug 11

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Apr 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: THRX 'nin kısa vadeli varlıkları ( $209.6M ) kısa vadeli yükümlülüklerini ( $7.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: THRX şirketinin kısa vadeli varlıkları ( $209.6M ) uzun vadeli yükümlülüklerini ( $3.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: THRX borçsuzdur.

Borcun Azaltılması: THRX un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: THRX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: THRX serbest nakit akışı her yıl % 51.3 2.9 yıl yetecek nakit akışına sahip olacaktır.

Theseus Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Theseus Pharmaceuticals Files Form 15

Theseus Pharmaceuticals' Common Stock to be Cease Trading on Nasdaq at the Opening of Trading on February 14, 2024, and Intends Promptly to Cause to be Delisted from Nasdaq

Theseus Pharmaceuticals, Inc. announced delayed 10-Q filing

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Recent updates

Theseus Pharmaceuticals Files Form 15

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from NASDAQ Composite Index

Concentra Biosciences, LLC completed the acquisition of Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX).

Theseus Pharmaceuticals' Common Stock to be Cease Trading on Nasdaq at the Opening of Trading on February 14, 2024, and Intends Promptly to Cause to be Delisted from Nasdaq

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Theseus Pharmaceuticals, Inc. Announces Employment Termination of Timothy P. Clackson as Chief Executive Officer, Effective December 7, 2023

Theseus Pharmaceuticals, Inc. announced delayed 10-Q filing

Key Executive exercised options to buy US$555k worth of stock.

New minor risk - Market cap size

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

New major risk - Share price stability

Price target decreased by 70% to US$6.75

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of The-630 in Patients with Gist

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Less than half of directors are independent

Theseus Pharmaceuticals Presents Preclinical Data Characterizing The-349, Its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium

Theseus Pharmaceuticals, Inc. Appoints Steven Stein to Board of Directors

Theseus Pharmaceuticals, Inc. Nominates The-349, A Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from Russell 2000 Growth Index

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

Less than half of directors are independent

Theseus Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Theseus Pharmaceuticals, Inc. Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (Egfr) Inhibitors At the 2022 American Association for Cancer Research (Aacr) Annual Meeting

Theseus Pharmaceuticals Announces First Patient Treated with The-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors

Less than half of directors are independent

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin